AT375803T - Adjuvant and methods for their verwendng - Google Patents

Adjuvant and methods for their verwendng

Info

Publication number
AT375803T
AT375803T AT99922832T AT99922832T AT375803T AT 375803 T AT375803 T AT 375803T AT 99922832 T AT99922832 T AT 99922832T AT 99922832 T AT99922832 T AT 99922832T AT 375803 T AT375803 T AT 375803T
Authority
AT
Austria
Prior art keywords
verwendng
adjuvant
methods
Prior art date
Application number
AT99922832T
Other languages
German (de)
Inventor
Glen Leesman
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US8467898P priority Critical
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of AT375803T publication Critical patent/AT375803T/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
AT99922832T 1998-05-07 1999-05-07 Adjuvant and methods for their verwendng AT375803T (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US8467898P true 1998-05-07 1998-05-07

Publications (1)

Publication Number Publication Date
AT375803T true AT375803T (en) 2007-11-15

Family

ID=22186530

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99922832T AT375803T (en) 1998-05-07 1999-05-07 Adjuvant and methods for their verwendng

Country Status (18)

Country Link
US (2) US6630161B1 (en)
EP (1) EP1075276B1 (en)
JP (1) JP2002513773A (en)
CN (2) CN1306438A (en)
AT (1) AT375803T (en)
AU (1) AU755445B2 (en)
BR (1) BR9910269A (en)
CA (1) CA2330610A1 (en)
CY (1) CY1107265T1 (en)
DE (1) DE69937343T2 (en)
DK (1) DK1075276T3 (en)
ES (1) ES2296390T3 (en)
HU (1) HU225844B1 (en)
NO (1) NO20005596L (en)
NZ (1) NZ508013A (en)
PT (1) PT1075276E (en)
WO (1) WO1999056776A2 (en)
ZA (1) ZA200006379B (en)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6491919B2 (en) * 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
AT375803T (en) * 1998-05-07 2007-11-15 Corixa Corp Adjuvant and methods for their verwendng
DE19859045A1 (en) 1998-12-21 2000-06-29 Fresenius Pharma Austria Gmbh Emulsion of oil in water with a protective effect against peroxidation damage to human organs, their preparation and use
US7915238B2 (en) * 1999-02-01 2011-03-29 Eisai R & D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6835721B2 (en) 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US20030031684A1 (en) * 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
US7351413B2 (en) 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
DE602004023921D1 (en) 2003-03-10 2009-12-17 Nycomed Gmbh New process for manufacturing vonroflumilast
CA2533581C (en) 2003-07-24 2012-05-08 Merial Limited Vaccine formulations comprising an oil-in-water emulsion
ZA200700457B (en) 2004-06-15 2008-08-27 New York Blood Ct Inc Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus
FR2873386B1 (en) 2004-07-22 2011-01-14 Agence Francaise De Securite Sanitaire Des Aliments Afssa vaccine composition against Rhodococcus equi
DE102004046235A1 (en) * 2004-09-22 2006-03-30 Altana Pharma Ag drug preparation
DK1861074T3 (en) 2005-03-16 2013-07-29 Takeda Gmbh The taste masked dosage form containing roflumilast
WO2006100111A1 (en) 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Composition
US7976852B2 (en) 2005-04-26 2011-07-12 Eisai R&D Management Co., Ltd. Compositions and methods for cancer immunotherapy
US20070292418A1 (en) * 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
EP1951302A2 (en) 2005-11-04 2008-08-06 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
EP2368572A3 (en) 2005-11-04 2013-04-24 Novartis Vaccines and Diagnostics S.r.l. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
EP1951298A1 (en) 2005-11-04 2008-08-06 Novartis Vaccines and Diagnostics S.r.l. Adjuvanted influenza vaccines including cytokine-inducing agents
DE06808434T1 (en) 2005-11-04 2009-12-17 Novartis Vaccines And Diagnostics S.R.L. Emulsions with free aqueous phases Tensid as adjuvant for gap-flu vaccines
WO2007079193A2 (en) 2005-12-30 2007-07-12 Tti Ellebeau, Inc. Iontophoretic systems, devices, and methods of delivery of active agents to biological interface
EP1976559B1 (en) 2006-01-27 2017-01-04 Novartis Influenza Vaccines Marburg GmbH Influenza vaccines containing hemagglutinin and matrix proteins
EP2010530A2 (en) * 2006-03-23 2009-01-07 Novartis AG Methods for the preparation of imidazole-containing compounds
US8063063B2 (en) * 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
EP2357184B1 (en) 2006-03-23 2015-02-25 Novartis AG Imidazoquinoxaline compounds as immunomodulators
CA2646349A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
WO2009030978A2 (en) 2006-06-09 2009-03-12 Novartis Ag Conformers of bacterial adhesins
WO2008009309A1 (en) 2006-07-17 2008-01-24 Glaxosmithkline Biologicals S.A. Influenza vaccine
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
US20100010199A1 (en) 2006-09-11 2010-01-14 Novartis Ag Making influenza virus vaccines without using eggs
AT555808T (en) 2006-09-26 2012-05-15 Infectious Disease Res Inst Vaccine composition with a synthetic adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PE01462009A1 (en) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa immunogenic composition against influenza virus
WO2008068631A2 (en) 2006-12-06 2008-06-12 Novartis Ag Vaccines including antigen from four strains of influenza virus
WO2008087803A1 (en) * 2007-01-16 2008-07-24 Hokkaido University Liposome preparation for iontophoresis having antioxidant component encapsulated therein
ES2393162T3 (en) 2007-06-27 2012-12-19 Novartis Ag influenza vaccines with a reduced additive content
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
KR101580660B1 (en) 2007-08-02 2015-12-28 바이오앤드백스 파마슈티칼즈, 리미티드. Multimeric multiepitope influenza vaccines
ES2588705T3 (en) 2007-09-27 2016-11-04 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
EP2889042A3 (en) 2008-03-18 2015-10-14 Novartis AG Improvements in preparation of influenza virus vaccine antigens
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
KR20110091560A (en) 2008-12-03 2011-08-11 프로테아 벡신 테크놀로지스 엘티디. Glutamyl trna synthetase (gts) fragments
EP2942062A1 (en) 2009-02-10 2015-11-11 Novartis AG Influenza vaccine regimens for pandemic-associated strains
AU2010212548A1 (en) 2009-02-10 2011-09-15 Novartis Ag Influenza vaccines with increased amounts of H3 antigen
EP2396032B1 (en) 2009-02-10 2016-09-28 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
EP2403526B1 (en) 2009-03-06 2019-05-15 GlaxoSmithKline Biologicals SA Chlamydia antigens
JP5830009B2 (en) 2009-04-14 2015-12-09 ノバルティス アーゲー Composition for immunizing against Staphylococcusaureus
MX360448B (en) 2009-06-05 2018-11-01 Infectious Disease Res Institute Synthetic glucopyranosyl lipid adjuvants.
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
JP2012532600A (en) 2009-07-07 2012-12-20 ノバルティス アーゲー Stored E. coli immunogen
EP2464658B1 (en) 2009-07-16 2014-10-01 Novartis AG Detoxified escherichia coli immunogens
AU2010292233B2 (en) 2009-09-10 2014-03-06 Boehringer Ingelheim Animal Health USA Inc. New vaccine formulations comprising saponin-containing adjuvants
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
AR074485A1 (en) * 2009-12-04 2011-01-19 Consejo Nac Invest Cient Tec Neoplastic or cancer vaccine lesions caused by human papillomavirus (HPV), methods, uses and methods
ES2707778T3 (en) 2009-12-30 2019-04-05 Glaxosmithkline Biologicals Sa Immunogens polysaccharides conjugated with carrier proteins of E. coli
US20110305748A1 (en) 2010-03-11 2011-12-15 Immune Design, Corp. Vaccines for Pandemic Influenza
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
AU2011268507B2 (en) 2010-06-25 2014-08-14 Novartis Ag Combinations of meningococcal factor H binding proteins
CA2828068C (en) 2011-02-22 2019-03-19 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
RU2013144207A (en) 2011-03-02 2015-04-10 Новартис Аг Combination vaccines with reduced doses of antigen and / or adjuvant
EA027236B1 (en) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
WO2012149307A2 (en) 2011-04-27 2012-11-01 Immune Design Corp. Synthetic long peptide (slp)-based vaccines
JP6240077B2 (en) 2011-10-06 2017-11-29 イムノバクシーン・テクノロジーズ・インコーポレイテッドImmunovaccine Technologies Inc. Tlr2 or activate, or liposomes compositions and the use thereof comprising an adjuvant to increase its activity
US20140248320A1 (en) 2011-10-20 2014-09-04 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
US20150044251A1 (en) 2011-12-23 2015-02-12 Novartis Ag Stable compositions for immunising against staphylococcus aureus
CN104363892A (en) * 2012-02-07 2015-02-18 传染性疾病研究院 Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
AU2013229432A1 (en) 2012-03-08 2014-10-16 Novartis Ag Adjuvanted formulations of booster vaccines
WO2013150518A1 (en) 2012-04-01 2013-10-10 Rappaport Family Institute For Research In The Medical Sciences Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
MX350274B (en) 2012-05-16 2017-08-31 Immune Design Corp Vaccines for hsv-2.
GB201212010D0 (en) * 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
JP6435261B2 (en) 2012-08-31 2018-12-05 ノバルティス アーゲー Proteins stabilized for immunization against Staphylococcusaureus
WO2014033191A1 (en) 2012-08-31 2014-03-06 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
BR112015005056A2 (en) 2012-09-06 2017-11-21 Novartis Ag combination vaccines with meningococcus serogroup d b / t / w
TR201808684T4 (en) 2012-10-02 2018-07-23 Glaxosmithkline Biologicals Sa Non-linear saccharide conjugates.
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
SG11201502599TA (en) 2012-10-12 2015-05-28 Glaxosmithkline Biolog Sa Non-cross-linked acellular pertussis antigens for use in combination vaccines
RS56886B1 (en) 2012-11-30 2018-04-30 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations
CA2894260A1 (en) 2012-12-18 2014-06-26 Glaxosmithkline Biologicals S.A. Conjugates for protecting against diphtheria and/or tetanus
JP6419775B2 (en) * 2013-03-19 2018-11-07 バイオテック ツールズ エスエー Allergen preparation
CN105209047A (en) 2013-04-18 2015-12-30 免疫设计股份有限公司 GLA monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
EP3069729A1 (en) 2015-03-17 2016-09-21 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
WO2016149417A1 (en) * 2015-03-17 2016-09-22 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20150086592A1 (en) 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
BR112017028011A2 (en) 2015-06-26 2018-08-28 Seqirus Uk Ltd corresponding influenza vaccines antigenically

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4258029A (en) * 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
ES8203612A1 (en) 1981-06-04 1982-04-01 Landerlan Sa Lab Globulin preparation process imuno native g li-ber anticomplementary activity
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US5656620A (en) * 1984-01-28 1997-08-12 Ismail; Roshdy Method for treating pain
US4857318A (en) * 1983-11-07 1989-08-15 Syntex (U.S.A.) Inc. Bordetella bronchiseptica pilus subunit protein vaccine effective against bordetella pertussis
US5026557A (en) * 1987-09-09 1991-06-25 The Liposome Company, Inc. Adjuvant composition
US5376369A (en) * 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
JPS6410499B2 (en) * 1987-11-20 1989-02-22 Toyama Chemical Co Ltd
EP0324455A3 (en) * 1988-01-15 1991-03-27 Hans O. Ribi Novel polymeric immunological adjuvants
HU198843B (en) * 1988-02-08 1989-12-28 Frigyes Kovacs Process for producing veterinary compositions with disinfecting and antiinflammatory action, comprising natural active ingredient and suitable particularly for treating mastitis
US5858769A (en) * 1989-05-15 1999-01-12 Akzo Nobel N.V. Device for detecting microorganisms
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JPH02152931A (en) * 1988-12-02 1990-06-12 Green Cross Corp:The Vaccine of hepatitis b
US5171737A (en) * 1989-03-03 1992-12-15 The Liposome Company, Inc. Emulsions
CA2017507C (en) * 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649013B1 (en) * 1989-07-03 1991-10-25 Seppic Sa Vaccines and fluids active principles of vectors containing a metabolizable oil
DE4019062A1 (en) * 1989-08-30 1991-03-07 Kali Chemie Ag Stabilising blood substitute emulsions contg. per:fluoro-hydrocarbon
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5709879A (en) * 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
US5324512A (en) 1990-12-26 1994-06-28 The Population Council [Gln']-luteinizing hormone releasing hormone conjugate of tetanus vaccine and its uses
US5387421A (en) * 1991-01-31 1995-02-07 Tsrl, Inc. Multi stage drug delivery system
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
ES2150493T5 (en) * 1993-05-25 2004-07-01 Wyeth Holdings Corporation Adjuvants for vaccines Respiratory Syncytial Virus.
US5773011A (en) * 1993-09-27 1998-06-30 Gerbu Biotechnik Gmbh Method of preparing a synergistic immunological adjuvant formulation
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
FR2715843B1 (en) * 1994-02-09 1996-04-12 Oreal antisun cosmetic compositions, method of preparation and use.
FR2716372B1 (en) * 1994-02-18 1996-04-12 Oreal stable cosmetic sunscreen compositions, fluids and / or flowable, method of preparation and use.
WO1995022989A1 (en) * 1994-02-24 1995-08-31 Micro-Pak, Inc. Vaccines containing paucilamellar lipid vesicles as immunological adjuvants
FR2716622B1 (en) * 1994-02-28 1996-04-12 Oreal Self-tanning cosmetic compositions based on dihydroxyacetone, method of preparation and use.
WO1996010397A1 (en) * 1994-09-30 1996-04-11 Takeda Chemical Industries, Ltd. Oral sustained-release preparation
GB9422990D0 (en) * 1994-11-15 1995-01-04 Cortecs Ltd Immunogenic compositions
IL117773A (en) * 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
DE59710082D1 (en) * 1996-12-13 2003-06-18 Vesifact Ag Baar Cosmetic preparations in the form of a nano-dispersion
US6110492A (en) * 1997-05-28 2000-08-29 Jenner Biotherapies, Inc. Immunogenic compositions
IS4518A (en) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group New formulations for vaccines
AT375803T (en) * 1998-05-07 2007-11-15 Corixa Corp Adjuvant and methods for their verwendng
EP1010717B1 (en) * 1998-12-18 2004-09-22 Shin-Etsu Chemical Co., Ltd. Oil-in-water emulsion of organopolysiloxane and method for the preparation thereof
US6288026B1 (en) * 1999-02-24 2001-09-11 Heinrich Exner Process and composition for treating diseases with an oil-in-water emulsion
US6551598B2 (en) * 2000-01-21 2003-04-22 Merial Vaccination against canine herpesvirosis and vaccines therefor

Also Published As

Publication number Publication date
PT1075276E (en) 2008-01-22
CN101219217A (en) 2008-07-16
BR9910269A (en) 2001-01-09
NZ508013A (en) 2003-08-29
AU755445B2 (en) 2002-12-12
US20030215497A1 (en) 2003-11-20
HU225844B1 (en) 2007-10-29
HU0101804A2 (en) 2001-11-28
DE69937343D1 (en) 2007-11-29
DE69937343T2 (en) 2008-07-24
EP1075276B1 (en) 2007-10-17
CN1306438A (en) 2001-08-01
CA2330610A1 (en) 1999-11-11
WO1999056776A3 (en) 2000-01-06
NO20005596D0 (en) 2000-11-06
US6630161B1 (en) 2003-10-07
ZA200006379B (en) 2002-01-07
HU0101804A3 (en) 2003-11-28
DK1075276T3 (en) 2008-02-11
JP2002513773A (en) 2002-05-14
WO1999056776A2 (en) 1999-11-11
AU3973799A (en) 1999-11-23
CY1107265T1 (en) 2012-11-21
ES2296390T3 (en) 2008-04-16
EP1075276A2 (en) 2001-02-14
NO20005596L (en) 2001-01-05

Similar Documents

Publication Publication Date Title
DE69937067D1 (en) Eindringungsfreies investigation system
DK1117502T3 (en) Welding method
AT224674T (en) clamping device
NO990531D0 (en) Particle-screen apparatus
AT300817T (en) Multiple access method and system
FI982490A0 (en) A method and system for communicating
DE69940220D1 (en) carrying device
NO996434D0 (en) Interkutan implant device
NO20011775L (en) Borefluidadditiver and methods thereof
DE69829256D1 (en) Tinstrahlaufzeichnungskopf and apparatus
DE59509423D1 (en) chuck
FI980135A0 (en) Inbyggt system
AT301835T (en) Eiweisbruchstückergänzungstests for proof biomolekularinteraktionen
DE19882938T1 (en) Koaxialkontaktanordnungs device
AT225455T (en) Shut-off
DE69738910D1 (en) Alignment and exposure method
DE60001321D1 (en) Hydrogen fuel-replenishing method and system
NO20003025L (en) retaining Block
DE69513300D1 (en) determination method
NO20003961D0 (en) Osteoimplantat and fremgangsmÕte for the preparation thereof
DE69940005D1 (en) Printing system and method
NO20012404L (en) Nanocapsules and method for preparation thereof
NO993217L (en) Broenntetningssammensetninger and methods
DE60044764D1 (en) Passage apparatus, and method
DE69920523D1 (en) chuck

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1075276

Country of ref document: EP

REN Ceased due to non-payment of the annual fee